Clinical Trials Browser

Phase 2 × NIH × ixazomib × Clear all

NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Phase 2 Completed

57 enrolled 22 charts

Hematologic Diseases, Multiple Myeloma

NCT01660997 2019-12-16

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma